2023 World Conference on Lung Cancer (Posters)-EP12.01. Response Evaluation of Newly Diagnosed EGFR Mutated NSCLC in Tertiary Referral Cancer Center in Jakarta-Indonesia

EP12.01. Response Evaluation of Newly Diagnosed EGFR Mutated NSCLC in Tertiary Referral Cancer Center in Jakarta-Indonesia - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the response evaluation of newly diagnosed EGFR mutated NSCLC patients in a tertiary referral cancer center in Jakarta, Indonesia. The study included 26 patients diagnosed with EGFR mutated NSCLC who visited the oncology clinic at the center from 2022. The patients' demographic data, smoking history, histologic subtype, EGFR mutation status, ALK rearrangement status, PD-L1 expression status, treatment history, and response were collected. Treatment response was measured based on RECIST 1.1 after 6 months of treatment.<br /><br />The results showed that the majority of the patients were females (50%) and the mean age was 61.6 years old. Adenocarcinoma histologic subtype was the most common (57.7%) among the patients. Point mutation exon 21 and deletion exon 19 were the most prevalent EGFR mutations (53.8%). The majority of the patients (65.3%) were in an advanced metastatic stage.<br /><br />Most patients (57.7%) were non-smokers and none had ALK translocation. Only a small percentage of patients (11.5%) had PD-L1 mutation. The majority of the patients (65.3%) received EGFR-TKI therapy with gefitinib, erlotinib, or afatinib. Among the patients who received EGFR-TKIs, most had minimally stable disease and only one patient showed progression.<br /><br />In conclusion, the study found that EGFR mutated NSCLC patients in this population were mostly adenocarcinoma histologic subtype, in a metastatic stage, and with point mutation exon 21 and deletion exon 19. The targeted therapy with EGFR-TKIs showed favorable outcomes, with most patients having stable disease.

Asset Subtitle

Devi Amelia

Meta Tag

Speaker Devi Amelia

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

response evaluation

EGFR mutated NSCLC

tertiary referral cancer center

Jakarta

histologic subtype

EGFR mutation status

ALK rearrangement status

PD-L1 expression status

treatment response

targeted therapy